BerGenBio AS, a Bergen, Norway-based oncology biopharmaceutical company, raised NOK75m (approximately $12.5m) in funding.
Backers included new and existing investors (Sarsia Seed AS and Investinor AS).
The company intends to use the funds for the development of its portfolio of innovative cancer therapeutics.
Led by Richard Godfrey, CEO, BerGenBio is developing BGB324, a selective Axl kinase inhibitor, which is currently in Phase Ib clinical studies to evaluate its safety and initial signs of efficacy to treat different cancers as a single agent and in combination with other drugs.
The company’s pipeline programs also include BGB001 and BGB002, which are at different stages of preclinical development.